Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477051 | 0.91 | KMT2A (0.83) | KMT2AKDM4ECYP1A2ALDH1A1KCNH2 | |
| SCHEMBL5482879 | 0.91 | KMT2A (0.83) | KMT2AKDM4ECYP1A2ALDH1A1KCNH2 | |
| SCHEMBL5486449 | 0.90 | KMT2A (0.81) | KMT2AKDM4ECYP1A2ALDH1A1KCNH2 | |
| SCHEMBL5475922 | 0.89 | KMT2A (0.80) | KMT2AKDM4ECYP1A2ALDH1A1KCNH2 | |
| SCHEMBL5479393 | 0.89 | KMT2A (0.80) | KMT2AKDM4ECYP1A2ALDH1A1KCNH2 | |
| SCHEMBL5486342 | 0.88 | KMT2A (0.78) | KMT2AKDM4ECYP1A2ALDH1A1KCNH2 | |
| SCHEMBL14492959 | 0.88 | KMT2A (0.78) | KMT2AKDM4ECYP1A2ALDH1A1KCNH2 | |
| SCHEMBL5483247 | 0.87 | KMT2A (0.77) | KMT2AKDM4ECYP1A2ALDH1A1KCNH2 | |
| SCHEMBL5479437 | 0.87 | KMT2A (0.76) | KMT2AKDM4ECYP1A2ALDH1A1KCNH2 | |
| SCHEMBL5482810 | 0.87 | KMT2A (0.76) | KMT2AKDM4ECYP1A2ALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | claimed |
| EP-2066655-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-06-10 | — | — | EP | claimed |
| WO-2008028935-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | claimed |
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| EP-2066655-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008028935-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | KCNJ2, KCNN2, KCNN1 | KMT2A 1374/4885KDM4E 1122/4885CYP1A2 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.